Moderna announces the departure of its commercial director Arpa Garay over the next few months (while remaining a consultant for a transitional period), as part of changes to the group's operating model in order to focus on its commercial objectives.

The messenger RNA specialist intends to concentrate on the continued sales of its Covid-19 vaccine, Spikevax, and the launch of its RSV vaccine in 2024, while preparing to launch several products a year from 2025.

To this end, CEO Stéphane Bancel will take over responsibility for sales and marketing in 2024, in direct liaison with the commercial team, and Stephen Hoge will assume responsibility for pipeline commercial strategy and medical affairs.

Copyright (c) 2023 CercleFinance.com. All rights reserved.